NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-064-2016-1-PCT-01 RSV F IMMUNOGENS AND THEIR USE PCT PCT COMB PCT/US2017/024714 Expired
NIAID E-064-2016-1-EP-05 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE EP National Stage 17720590.3 Pending
NIAID E-064-2016-1-CA-03 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE CA National Stage 3015570 Pending
NCI E-233-2014-0-US-07 METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION US National Stage 15/514,942 Abandoned
NCATS E-116-2016-0-JP-07 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE JP National Stage 2018-550320 Issued
NCATS E-116-2016-0-CA-04 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE CA National Stage 3018959 Issued
NCATS E-116-2016-0-JP-11 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE JP DIV 2022-041167 Issued
NIAID E-076-2015-4-NZ-16 METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION NZ National Stage 2073-05-11 Issued
NCATS E-116-2016-0-CN-05 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE CN National Stage 201780027680.8 Issued
NCATS E-116-2016-0-AU-03 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE AU National Stage 2017238859 Issued
NHLBI E-253-2014-0-US-04 Segmented Metallic Guidewires US National Stage 15/514,744 10695540 Issued PDF
NCATS E-116-2016-0-PCT-02 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE PCT PCT PCT/US17/024241 Expired
NCATS E-036-2016-0-PCT-02 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders PCT PCT PCT/US2017/024238 Expired
NCATS E-036-2016-0-EP-06 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders EP National Stage 17716697.2 Abandoned
NCATS E-036-2016-0-AU-03 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders AU National Stage 2017238858 Abandoned
NIAID E-076-2015-5-NZ-16 METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES NZ National Stage 2073-05-20 Abandoned
NCATS E-036-2016-0-CA-04 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders CA National Stage 3019012 Abandoned
NIAID E-181-2014-0-US-06 Virus-Based Expression Vectors and Use Thereof US National Stage 15/514,119 10894966 Issued PDF
NICHD E-052-2020-0-US-01 MUELLER MATRIX POLARIZATION IMAGING FOR PRETERM BIRTH ASSESSMENT US ORD 15/468,763 10791983 Issued PDF
NIAID E-188-2015-0-EP-03 POLYMER ADJUVANT EP National Stage 15781141.5 Pending
NHLBI E-139-2017-0-US-01 ApoC-II Mimetic Peptides US 62/476,531 Abandoned
CC E-076-2017-0-US-01 Method And System Of Building Hospital-scale Chest X-ray Database For Entity Extraction And Weakly-Supervised Classification And Localization Of Common Thorax Diseases US 62/476,029 Abandoned
NHLBI E-134-2017-1-US-01 Methods of Treating Hypertriglyceridemia with ApoC-llA Mimetic Petides US 62/476,535 Abandoned
NCI E-116-2017-0-US-01 Compositions and Methods For Treating Cancer With Anti-CD33 Immunotherapy US 62/476,438 Abandoned
NIAID E-083-2017-0-US-01 Glycan-Masked Engineered Outer Domains of HIV-1 GP120 and Their Use US 62/476,397 Abandoned
NIAID E-242-2011-0-CA-03 Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Crystal Structures and Deep Sequencing CA National Stage 2835522 Issued
NLM E-107-2010-2-US-06 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 15/440,826 10041938 Issued PDF
NCI E-148-2011-0-CA-04 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer CA National Stage 2832540 Issued
NIBIB E-225-2014-0-US-04 Resolution Enhancement for Line Scanning Excitation Microscopy Systems and Methods US National Stage 15/512,870 10247930 Abandoned PDF
NHLBI E-037-2011-0-US-10 Development Of A Novel HDL Based Hydrophobic Drug Delivery System Using Amphipathic Peptides US CON 15/465,363 Abandoned
NIAID E-145-2015-3-US-02 Substituted Phenylpyrrolecarboxamides With Therapeutic Activity In HIV US National Stage 15/512,493 10137107 Issued PDF
NCI E-250-2014-0-US-04 ANTI-CD276 ANTIBODIES (B7H3) US National Stage 15/512,000 10604582 Issued PDF
NCI E-130-2016-0-PCT-02 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT PCT PCT PCT/US2017/022783 Expired
NCI E-205-2016-0-EP-03 Nanoparticle to Target Cancer EP National Stage 17767463.7 Issued
NCI E-205-2016-0-GB-01 Nanoparticle to Target Cancer GB EP 17767463.7 Issued
NCI E-205-2016-0-DE-01 Nanoparticle to Target Cancer DE EP 17767463.7 Issued
NCI E-205-2016-0-FR-01 Nanoparticle to Target Cancer FR EP 17767463.7 Issued
NCI E-130-2011-0-HK-15 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof HK EP 17102681.1 Issued
NCI E-205-2016-0-PCT-02 Nanoparticle to Target Cancer PCT PCT PCT/US2017/022567 Expired
NCI E-229-2018-0-PCT-02 AZA-A-RING INDENOISOQUINOLINE TOPOISOMERASE I POISONS PCT PCT PCT/US2017/022389 Expired
NCI E-267-2015-1-US-01 Inhibitors Of Prokaryotic Gene Transcription and Uses Thereof US 62/471,681 Abandoned
NCI E-205-2016-0-CA-04 Nanoparticle to Target Cancer CA National Stage 3017517 Pending
NICHD E-157-2011-0-US-05 SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME US DIV 15/458,234 Abandoned
NIAID E-076-2015-4-ZA-21 METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION ZA National Stage 2017/01815 Pending
NIA E-045-2012-0-US-04 THIO COMPOUNDS US DIV 15/457,156 10220028 Issued PDF
NIAID E-118-2016-0-PCT-02 Live Attenuated Zika Virus Vaccine PCT PCT PCT/US2017/021989 Expired
NIAID E-118-2016-0-CO-07 Live Attenuated Zika Virus Vaccine CO National Stage NC2018/0010874 Abandoned
NIAID E-118-2016-0-CN-06 Live Attenuated Zika Virus Vaccine CN National Stage 201780028836.4 Abandoned
NIAID E-118-2016-0-JP-10 Live Attenuated Zika Virus Vaccine JP National Stage 2018-547931 Abandoned
NIAID E-118-2016-0-IN-09 Live Attenuated Zika Virus Vaccine IN National Stage 201817036778 Abandoned